The entire output should use the format provided. Drug Development Progress: Positive clinical trial results for AKAN's drug candidates typically drive the stock price up, while setbacks cause declines.

Regulatory Approvals: FDA approval of AKAN's products significantly increases the stock's value, reflecting potential revenue streams. Rejections have the opposite effect.

Market Sentiment: General investor optimism or pessimism towards biotech stocks can influence AKAN's price, regardless of company-specific news.

Financial Performance: Strong revenue growth and profitability improve investor confidence, leading to higher stock prices. Losses can decrease the price.

Competition: The emergence of competing drugs or therapies can negatively affect AKAN's potential market share and thus, its stock price.

Partnerships & Acquisitions: Strategic collaborations or potential acquisition deals often boost the stock price, signaling future growth or value realization.

Overall Economic Conditions: Broad economic downturns or recessions can negatively impact investor appetite for riskier assets like biotech stocks.

Company News & Announcements: Major announcements regarding new products, research advancements, or leadership changes influence investor perception and stock price.

Analyst Ratings & Reports: Positive ratings from financial analysts can attract investors, driving the price up. Negative ratings can lead to sell-offs.

Debt and Cash Position: A strong balance sheet with ample cash and low debt makes the company more attractive to investors. High debt can raise concerns.